Loading…
Effectiveness, Simplification and Persistence of IDegLira in Poorly Controlled People with Type 2 Diabetes: A 4-Year Follow-Up Real-World Study
Introduction Efficacy and safety of the fixed ratio combination of insulin degludec and liraglutide (IDegLira) has been largely documented. However, long-term data are limited. This study aimed at describing persistence in therapy and the effectiveness at 48 months of IDegLira. Methods We conducted...
Saved in:
| Published in: | Diabetes therapy 2024-06, Vol.15 (6), p.1313-1331 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c493t-987e7cec9f3325c623b298495b9fe92281a3b70a7985af9c666b8c3e0be3ad6f3 |
| container_end_page | 1331 |
| container_issue | 6 |
| container_start_page | 1313 |
| container_title | Diabetes therapy |
| container_volume | 15 |
| creator | Di Loreto, Chiara Celleno, Roberta Pezzuto, Debora Ambrosi, Franca Bellavita, Silvia Biagini, Marinella Passeri, Monica Del Sindaco, Paola |
| description | Introduction
Efficacy and safety of the fixed ratio combination of insulin degludec and liraglutide (IDegLira) has been largely documented. However, long-term data are limited. This study aimed at describing persistence in therapy and the effectiveness at 48 months of IDegLira.
Methods
We conducted an observational study based on retrospective chart review. All patients treated with IDegLira during 2018–2022 were included. Data on treatment approaches and clinical outcomes were collected at the first prescription of IDegLira (T0) and after 6, 12, 24, 36, and 48 months.
Results
Overall, 156 patients (mean age 68 years, 64.1% men) started IDegLira, of whom 88 (56.4%) were previously treated with basal-oral therapy (BOT) and 68 (43.6%) with basal-bolus schemes (BB). Before starting IDegLira, 23.8% were treated with ≥ 2 oral antihyperglycemic agents in association with insulin; at T0, the proportion decreased to 3.2%. Short-acting insulin was discontinued after the first week. After 48 months, levels of HbA1c were significantly reduced by 1.34% in the BOT group and 1.07% in the BB group (
p
|
| doi_str_mv | 10.1007/s13300-024-01564-z |
| format | article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11096145</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A794037667</galeid><sourcerecordid>A794037667</sourcerecordid><originalsourceid>FETCH-LOGICAL-c493t-987e7cec9f3325c623b298495b9fe92281a3b70a7985af9c666b8c3e0be3ad6f3</originalsourceid><addsrcrecordid>eNp9kl1rFDEUhgdRbKn9A15IwBsvnJqPmczEG1m2n7BgsS3iVchkTrYp2WRMZlu2f8K_bNatayticpGQ87xvOIe3KF4TfEAwbj4kwhjGJaZViUnNq_L-WbFLWi5KLjh5vr3XbKfYT-kG58WEEIS8LHZYy3FNm3q3-HFkDOjR3oKHlN6jC7sYnDVWq9EGj5Tv0TnEZNMIXgMKBp0dwnxmo0LWo_MQoluhafBjDM7BGg6DA3Rnx2t0uRoAUXRoVQcjpI9ogqryG6iIjjMc7sqrAX0B5cqv2aVHF-OyX70qXhjlEuw_nHvF1fHR5fS0nH0-OZtOZqWuBBtL0TbQaNDCMEZrzSnrqGgrUXfCgKC0JYp1DVaNaGtlhOacd61mgDtgqueG7RWfNr7DsltAryF3oJwcol2ouJJBWfm04u21nIdbSQjO863q7PDuwSGG70tIo1zYpME55SEsk2SYtRXlFaMZffsXehOW0ef-MlXXtGoxf0TNlQNpvQn5Y702lZNGVJg1nDeZOvgHlXcPC6uDB2Pz-xMB3Qh0DClFMNsmCZbrKMlNlGSOkvwVJXmfRW8ej2cr-R2cDLANkHLJzyH-aek_tj8BepXT0Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3055248062</pqid></control><display><type>article</type><title>Effectiveness, Simplification and Persistence of IDegLira in Poorly Controlled People with Type 2 Diabetes: A 4-Year Follow-Up Real-World Study</title><source>Nexis UK</source><source>Springer Nature - SpringerLink Journals - Fully Open Access </source><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Di Loreto, Chiara ; Celleno, Roberta ; Pezzuto, Debora ; Ambrosi, Franca ; Bellavita, Silvia ; Biagini, Marinella ; Passeri, Monica ; Del Sindaco, Paola</creator><creatorcontrib>Di Loreto, Chiara ; Celleno, Roberta ; Pezzuto, Debora ; Ambrosi, Franca ; Bellavita, Silvia ; Biagini, Marinella ; Passeri, Monica ; Del Sindaco, Paola</creatorcontrib><description>Introduction
Efficacy and safety of the fixed ratio combination of insulin degludec and liraglutide (IDegLira) has been largely documented. However, long-term data are limited. This study aimed at describing persistence in therapy and the effectiveness at 48 months of IDegLira.
Methods
We conducted an observational study based on retrospective chart review. All patients treated with IDegLira during 2018–2022 were included. Data on treatment approaches and clinical outcomes were collected at the first prescription of IDegLira (T0) and after 6, 12, 24, 36, and 48 months.
Results
Overall, 156 patients (mean age 68 years, 64.1% men) started IDegLira, of whom 88 (56.4%) were previously treated with basal-oral therapy (BOT) and 68 (43.6%) with basal-bolus schemes (BB). Before starting IDegLira, 23.8% were treated with ≥ 2 oral antihyperglycemic agents in association with insulin; at T0, the proportion decreased to 3.2%. Short-acting insulin was discontinued after the first week. After 48 months, levels of HbA1c were significantly reduced by 1.34% in the BOT group and 1.07% in the BB group (
p
< 0.0001 in both groups). In the BOT group, FBG levels decreased by about 50 mg/dl and body weight was unchanged. In the BB group, FBG levels decreased by about 40 mg/dl and body weight was significantly reduced by an average of 7.7 kg. Five patients (3.2%) interrupted therapy with IDegLira during 48 months, and no severe hypoglycemia occurred.
Conclusions
Our study emphasizes the important role of IDegLira in maintaining a good metabolic control while minimizing the risk of major hypoglycemia and weight gain in the long term. The substantial simplification of treatment schemes can increase adherence.</description><identifier>ISSN: 1869-6953</identifier><identifier>EISSN: 1869-6961</identifier><identifier>DOI: 10.1007/s13300-024-01564-z</identifier><identifier>PMID: 38605275</identifier><language>eng</language><publisher>Cheshire: Springer Healthcare</publisher><subject>Antidiabetics ; Body mass index ; Cardiology ; Chronic illnesses ; Clinical medicine ; Diabetes ; Diagnosis ; Dosage and administration ; Drug therapy ; Endocrinology ; Glucagon ; Glucose ; Glycosylated hemoglobin ; Health aspects ; Hypoglycemia ; Hypoglycemic agents ; Insulin ; Internal Medicine ; Measurement ; Medicine ; Medicine & Public Health ; Metabolism ; Observational studies ; Original Research ; Patient outcomes ; Patients ; Type 2 diabetes</subject><ispartof>Diabetes therapy, 2024-06, Vol.15 (6), p.1313-1331</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>COPYRIGHT 2024 Springer</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c493t-987e7cec9f3325c623b298495b9fe92281a3b70a7985af9c666b8c3e0be3ad6f3</cites><orcidid>0009-0003-4834-5761</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3055248062/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3055248062?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,74998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38605275$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Di Loreto, Chiara</creatorcontrib><creatorcontrib>Celleno, Roberta</creatorcontrib><creatorcontrib>Pezzuto, Debora</creatorcontrib><creatorcontrib>Ambrosi, Franca</creatorcontrib><creatorcontrib>Bellavita, Silvia</creatorcontrib><creatorcontrib>Biagini, Marinella</creatorcontrib><creatorcontrib>Passeri, Monica</creatorcontrib><creatorcontrib>Del Sindaco, Paola</creatorcontrib><title>Effectiveness, Simplification and Persistence of IDegLira in Poorly Controlled People with Type 2 Diabetes: A 4-Year Follow-Up Real-World Study</title><title>Diabetes therapy</title><addtitle>Diabetes Ther</addtitle><addtitle>Diabetes Ther</addtitle><description>Introduction
Efficacy and safety of the fixed ratio combination of insulin degludec and liraglutide (IDegLira) has been largely documented. However, long-term data are limited. This study aimed at describing persistence in therapy and the effectiveness at 48 months of IDegLira.
Methods
We conducted an observational study based on retrospective chart review. All patients treated with IDegLira during 2018–2022 were included. Data on treatment approaches and clinical outcomes were collected at the first prescription of IDegLira (T0) and after 6, 12, 24, 36, and 48 months.
Results
Overall, 156 patients (mean age 68 years, 64.1% men) started IDegLira, of whom 88 (56.4%) were previously treated with basal-oral therapy (BOT) and 68 (43.6%) with basal-bolus schemes (BB). Before starting IDegLira, 23.8% were treated with ≥ 2 oral antihyperglycemic agents in association with insulin; at T0, the proportion decreased to 3.2%. Short-acting insulin was discontinued after the first week. After 48 months, levels of HbA1c were significantly reduced by 1.34% in the BOT group and 1.07% in the BB group (
p
< 0.0001 in both groups). In the BOT group, FBG levels decreased by about 50 mg/dl and body weight was unchanged. In the BB group, FBG levels decreased by about 40 mg/dl and body weight was significantly reduced by an average of 7.7 kg. Five patients (3.2%) interrupted therapy with IDegLira during 48 months, and no severe hypoglycemia occurred.
Conclusions
Our study emphasizes the important role of IDegLira in maintaining a good metabolic control while minimizing the risk of major hypoglycemia and weight gain in the long term. The substantial simplification of treatment schemes can increase adherence.</description><subject>Antidiabetics</subject><subject>Body mass index</subject><subject>Cardiology</subject><subject>Chronic illnesses</subject><subject>Clinical medicine</subject><subject>Diabetes</subject><subject>Diagnosis</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Endocrinology</subject><subject>Glucagon</subject><subject>Glucose</subject><subject>Glycosylated hemoglobin</subject><subject>Health aspects</subject><subject>Hypoglycemia</subject><subject>Hypoglycemic agents</subject><subject>Insulin</subject><subject>Internal Medicine</subject><subject>Measurement</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolism</subject><subject>Observational studies</subject><subject>Original Research</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Type 2 diabetes</subject><issn>1869-6953</issn><issn>1869-6961</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp9kl1rFDEUhgdRbKn9A15IwBsvnJqPmczEG1m2n7BgsS3iVchkTrYp2WRMZlu2f8K_bNatayticpGQ87xvOIe3KF4TfEAwbj4kwhjGJaZViUnNq_L-WbFLWi5KLjh5vr3XbKfYT-kG58WEEIS8LHZYy3FNm3q3-HFkDOjR3oKHlN6jC7sYnDVWq9EGj5Tv0TnEZNMIXgMKBp0dwnxmo0LWo_MQoluhafBjDM7BGg6DA3Rnx2t0uRoAUXRoVQcjpI9ogqryG6iIjjMc7sqrAX0B5cqv2aVHF-OyX70qXhjlEuw_nHvF1fHR5fS0nH0-OZtOZqWuBBtL0TbQaNDCMEZrzSnrqGgrUXfCgKC0JYp1DVaNaGtlhOacd61mgDtgqueG7RWfNr7DsltAryF3oJwcol2ouJJBWfm04u21nIdbSQjO863q7PDuwSGG70tIo1zYpME55SEsk2SYtRXlFaMZffsXehOW0ef-MlXXtGoxf0TNlQNpvQn5Y702lZNGVJg1nDeZOvgHlXcPC6uDB2Pz-xMB3Qh0DClFMNsmCZbrKMlNlGSOkvwVJXmfRW8ej2cr-R2cDLANkHLJzyH-aek_tj8BepXT0Q</recordid><startdate>20240601</startdate><enddate>20240601</enddate><creator>Di Loreto, Chiara</creator><creator>Celleno, Roberta</creator><creator>Pezzuto, Debora</creator><creator>Ambrosi, Franca</creator><creator>Bellavita, Silvia</creator><creator>Biagini, Marinella</creator><creator>Passeri, Monica</creator><creator>Del Sindaco, Paola</creator><general>Springer Healthcare</general><general>Springer</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0009-0003-4834-5761</orcidid></search><sort><creationdate>20240601</creationdate><title>Effectiveness, Simplification and Persistence of IDegLira in Poorly Controlled People with Type 2 Diabetes: A 4-Year Follow-Up Real-World Study</title><author>Di Loreto, Chiara ; Celleno, Roberta ; Pezzuto, Debora ; Ambrosi, Franca ; Bellavita, Silvia ; Biagini, Marinella ; Passeri, Monica ; Del Sindaco, Paola</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c493t-987e7cec9f3325c623b298495b9fe92281a3b70a7985af9c666b8c3e0be3ad6f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antidiabetics</topic><topic>Body mass index</topic><topic>Cardiology</topic><topic>Chronic illnesses</topic><topic>Clinical medicine</topic><topic>Diabetes</topic><topic>Diagnosis</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Endocrinology</topic><topic>Glucagon</topic><topic>Glucose</topic><topic>Glycosylated hemoglobin</topic><topic>Health aspects</topic><topic>Hypoglycemia</topic><topic>Hypoglycemic agents</topic><topic>Insulin</topic><topic>Internal Medicine</topic><topic>Measurement</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolism</topic><topic>Observational studies</topic><topic>Original Research</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Type 2 diabetes</topic><toplevel>online_resources</toplevel><creatorcontrib>Di Loreto, Chiara</creatorcontrib><creatorcontrib>Celleno, Roberta</creatorcontrib><creatorcontrib>Pezzuto, Debora</creatorcontrib><creatorcontrib>Ambrosi, Franca</creatorcontrib><creatorcontrib>Bellavita, Silvia</creatorcontrib><creatorcontrib>Biagini, Marinella</creatorcontrib><creatorcontrib>Passeri, Monica</creatorcontrib><creatorcontrib>Del Sindaco, Paola</creatorcontrib><collection>SpringerOpen</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetes therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Di Loreto, Chiara</au><au>Celleno, Roberta</au><au>Pezzuto, Debora</au><au>Ambrosi, Franca</au><au>Bellavita, Silvia</au><au>Biagini, Marinella</au><au>Passeri, Monica</au><au>Del Sindaco, Paola</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness, Simplification and Persistence of IDegLira in Poorly Controlled People with Type 2 Diabetes: A 4-Year Follow-Up Real-World Study</atitle><jtitle>Diabetes therapy</jtitle><stitle>Diabetes Ther</stitle><addtitle>Diabetes Ther</addtitle><date>2024-06-01</date><risdate>2024</risdate><volume>15</volume><issue>6</issue><spage>1313</spage><epage>1331</epage><pages>1313-1331</pages><issn>1869-6953</issn><eissn>1869-6961</eissn><abstract>Introduction
Efficacy and safety of the fixed ratio combination of insulin degludec and liraglutide (IDegLira) has been largely documented. However, long-term data are limited. This study aimed at describing persistence in therapy and the effectiveness at 48 months of IDegLira.
Methods
We conducted an observational study based on retrospective chart review. All patients treated with IDegLira during 2018–2022 were included. Data on treatment approaches and clinical outcomes were collected at the first prescription of IDegLira (T0) and after 6, 12, 24, 36, and 48 months.
Results
Overall, 156 patients (mean age 68 years, 64.1% men) started IDegLira, of whom 88 (56.4%) were previously treated with basal-oral therapy (BOT) and 68 (43.6%) with basal-bolus schemes (BB). Before starting IDegLira, 23.8% were treated with ≥ 2 oral antihyperglycemic agents in association with insulin; at T0, the proportion decreased to 3.2%. Short-acting insulin was discontinued after the first week. After 48 months, levels of HbA1c were significantly reduced by 1.34% in the BOT group and 1.07% in the BB group (
p
< 0.0001 in both groups). In the BOT group, FBG levels decreased by about 50 mg/dl and body weight was unchanged. In the BB group, FBG levels decreased by about 40 mg/dl and body weight was significantly reduced by an average of 7.7 kg. Five patients (3.2%) interrupted therapy with IDegLira during 48 months, and no severe hypoglycemia occurred.
Conclusions
Our study emphasizes the important role of IDegLira in maintaining a good metabolic control while minimizing the risk of major hypoglycemia and weight gain in the long term. The substantial simplification of treatment schemes can increase adherence.</abstract><cop>Cheshire</cop><pub>Springer Healthcare</pub><pmid>38605275</pmid><doi>10.1007/s13300-024-01564-z</doi><tpages>19</tpages><orcidid>https://orcid.org/0009-0003-4834-5761</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1869-6953 |
| ispartof | Diabetes therapy, 2024-06, Vol.15 (6), p.1313-1331 |
| issn | 1869-6953 1869-6961 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11096145 |
| source | Nexis UK; Springer Nature - SpringerLink Journals - Fully Open Access ; Publicly Available Content (ProQuest); PubMed Central |
| subjects | Antidiabetics Body mass index Cardiology Chronic illnesses Clinical medicine Diabetes Diagnosis Dosage and administration Drug therapy Endocrinology Glucagon Glucose Glycosylated hemoglobin Health aspects Hypoglycemia Hypoglycemic agents Insulin Internal Medicine Measurement Medicine Medicine & Public Health Metabolism Observational studies Original Research Patient outcomes Patients Type 2 diabetes |
| title | Effectiveness, Simplification and Persistence of IDegLira in Poorly Controlled People with Type 2 Diabetes: A 4-Year Follow-Up Real-World Study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T16%3A13%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness,%20Simplification%20and%20Persistence%20of%20IDegLira%20in%20Poorly%20Controlled%20People%20with%20Type%202%20Diabetes:%20A%204-Year%20Follow-Up%20Real-World%20Study&rft.jtitle=Diabetes%20therapy&rft.au=Di%20Loreto,%20Chiara&rft.date=2024-06-01&rft.volume=15&rft.issue=6&rft.spage=1313&rft.epage=1331&rft.pages=1313-1331&rft.issn=1869-6953&rft.eissn=1869-6961&rft_id=info:doi/10.1007/s13300-024-01564-z&rft_dat=%3Cgale_pubme%3EA794037667%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c493t-987e7cec9f3325c623b298495b9fe92281a3b70a7985af9c666b8c3e0be3ad6f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3055248062&rft_id=info:pmid/38605275&rft_galeid=A794037667&rfr_iscdi=true |